Abstract
The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next generation agent. The recent AXIS trial reported on axitinib's efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients.
| Original language | English |
|---|---|
| Journal | OncoTargets and Therapy |
| Volume | 5 |
| Pages (from-to) | 111-117 |
| Number of pages | 7 |
| ISSN | 1178-6930 |
| DOIs | |
| Publication status | Published - 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)
Fingerprint
Dive into the research topics of 'Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver